FDA Approves NOXAFIL — Merck Sharp & Dohme LLC

# FDA Approves Merck's NOXAFIL (Posaconazole) Oral Formulation Merck Sharp & Dohme LLC has received FDA approval for an oral formulation of NOXAFIL (posaconazole), potentially expanding the antifungal treatment market by offering patients an alternative to intravenous administration and improving accessibility for broader patient populations. The approval could strengthen Merck's position in the fungal infection treatment segment while potentially capturing market share from existing therapeutic options.